Biotek-snakken — Februar 2021
-
-
Sarepta får FDA godkendelse af AMONDY 45 for behandling af Duchenne Muscular Dystrophy. Mon dette kan stoppe udsalgsvanviddet i Hansa Bio, der netop startede med et fejlet studie af Sarepta i DMD d. 7/1-21.
-
I øvrigt skulle pibekoret inde i nabochatten prøve at være Hansa-investor, nede med 33,82 % i år, mod Genmabs 15,06 % for året. - ved godt at mange af os har investeringer i begge selskaber (-:
-
XBrane webcast.... https://tv.streamfabriken.com/2021-02-24-xbrane-biopharma
-
Så kom den som forventet. Mon ikke den stryger over 200 i morgen ? https://www.oncopeptides.com/en/media/press-releases/fda-approves-oncopeptides-pepaxto--melphalan-flufenamide-for-patients-with-relapsed-or-refractory-multiple-myeloma
-
Orphazyme: 2 sides artikel i P&P i går. "Gode kort på hånden foryd for første produktgodkendelse" Focus på FDA´s svar 17/6 - Interview med FHA fra HCA der der solidt potentiale i pipine men også one product company risk
-
Velbekomme @fandel - god we
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind